vokanamet 50 mg / 850 mg filmtabletten
janssen-cilag ag - canagliflozinum, metformini hydrochloridum - filmtabletten - canagliflozinum 50 mg ut canagliflozinum hemihydricum, metformini hydrochloridum 850 mg, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum corresp. natrium 2.6649 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - orales antidiabetikum - synthetika
vokanamet 50 mg / 1000 mg filmtabletten
janssen-cilag ag - canagliflozinum, metformini hydrochloridum - filmtabletten - canagliflozinum 50 mg ut canagliflozinum hemihydricum, metformini hydrochloridum 1000 mg, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum corresp. natrium 3.1066 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - orales antidiabetikum - synthetika
vokanamet 150 mg / 850 mg filmtabletten
janssen-cilag ag - canagliflozinum, metformini hydrochloridum - filmtabletten - canagliflozinum 150 mg ut canagliflozinum hemihydricum, metformini hydrochloridum 850 mg, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum corresp. natrium 3.745 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto. - orales antidiabetikum - synthetika
vokanamet 150 mg / 1000 mg filmtabletten
janssen-cilag ag - canagliflozinum, metformini hydrochloridum - filmtabletten - canagliflozinum 150 mg ut canagliflozinum hemihydricum, metformini hydrochloridum 1000 mg, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum corresp. natrium 3.4314 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - orales antidiabetikum - synthetika
terbinafin puren 250 mg tabletten
puren pharma gmbh & co. kg (8034441) - terbinafinhydrochlorid - tablette - terbinafinhydrochlorid (22544) 281,25 milligramm
alunbrig
takeda pharma a/s - brigatinib - karzinom, nicht kleinzellige lunge - antineoplastische mittel - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
eumovate 0,05 % salbe
glaxosmithkline pharmaceuticals - clobetasone butyrate - salbe - 0,05 % - clobetasone butyrate 0.5 mg/g - clobetasone
eumovate 0,05 % creme
glaxosmithkline pharmaceuticals - clobetasone butyrate - creme - 0,05 % - clobetasone butyrate 0.5 mg/g - clobetasone
colibiogen inject
laves-arzneimittel gmbh (3082518) - escherichia-coli-stoffwechselprodukte, eiweißfrei - injektionslösung - teil 1 - injektionslösung; escherichia-coli-stoffwechselprodukte, eiweißfrei (05366) 540 millionkeime
synerga
laves-arzneimittel gmbh (3082518) - escherichia-coli-stoffwechselprodukte, eiweißfrei - tropfen - escherichia-coli-stoffwechselprodukte, eiweißfrei (05366) 9,3 milliliter